Product image of Olmesartan+amlodipine Sandoz (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olmesartan+amlodipine Sandoz

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olmesartan+amlodipine Sandoz (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan+amlodipine Sandoz, is a angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond monotherapy.

GNH India supplies Olmesartan+amlodipine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Sandoz Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan+amlodipine Sandoz is used in cardiovascular therapy to manage high blood pressure through complementary mechanisms.

  • Hypertension: Provides additive blood pressure reduction when monotherapy is insufficient.
  • Isolated systolic hypertension in the elderly: Improves systolic control with a calcium‑channel blocker component.
  • Hypertensive patients with concomitant edema risk: Amlodipine’s vasodilatory effect mitigates fluid retention associated with some antihypertensives.

How It Works

  • Olmesartan medoxil selectively blocks the AT1 subtype of angiotensin II receptors, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combination yields complementary blood‑pressure lowering effects without competing for the same molecular target.

Side Effects

Adverse reactions reported with the fixed‑dose combination reflect the safety profiles of both components.

Common Side Effects

  • Peripheral edema: mild swelling, often of the ankles.
  • Headache: transient, pressure‑type pain.
  • Dizziness or light‑headedness: especially after the first doses.
  • Flushing: warm sensation, usually short‑lived.
  • Fatigue: general tiredness without a clear cause.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of lips, tongue or airway.
  • Severe hypotension: symptomatic low blood pressure.
  • Hepatic dysfunction: elevated liver enzymes or jaundice.
  • Cardiac arrhythmias: irregular heart rhythm.
  • Stevens‑Johnson syndrome: severe skin reaction.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

  • Renal impairment: adjust dose and monitor creatinine clearance.
  • Hepatic disease: use with caution, observe liver function tests.
  • Electrolyte disturbances: check potassium and sodium levels.
  • Concomitant antihypertensives: avoid excessive blood‑pressure lowering.
  • Pregnancy: contraindicated in the second and third trimesters; discuss risks.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Avoid Interactions

Olmesartan+amlodipine Sandoz may alter the pharmacokinetics or pharmacodynamics of several co‑administered medicines.

Major Interactions (Avoid)

  • Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal failure.
  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine exposure.

Moderate Interactions (Monitor Closely)

  • Diuretics: may potentiate hypotensive effect.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive efficacy and affect renal function.
  • Lithium: may increase serum lithium levels.
  • Simvastatin: higher risk of myopathy when combined with amlodipine.
  • Digoxin: monitor serum levels due to possible increased concentration.

Frequently Asked Questions

Olmesartan+amlodipine Sandoz is a fixed‑dose oral tablet that combines an angiotensin‑II receptor blocker with a calcium‑channel blocker. It is prescribed to lower high blood pressure in adults when a single‑agent regimen does not achieve target values, providing complementary mechanisms to improve cardiovascular risk management.

Olmesartan medoxil blocks AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone‑mediated fluid retention. Amlodipine, the second component, inhibits calcium entry into vascular smooth‑muscle cells, causing arterial dilation. Together they produce additive blood‑pressure reduction without competing for the same molecular target.

The prescribed dose of Olmesartan+amlodipine Sandoz is determined by the treating physician based on the patient’s blood‑pressure level, response to therapy, and any comorbid conditions. Dosage adjustments are made according to clinical guidelines and individual tolerance.

Olmesartan+amlodipine Sandoz is contraindicated in the second and third trimesters of pregnancy because angiotensin‑II receptor blockers can harm the fetus. Safety during breastfeeding has not been established; therefore, it should be used only if the potential benefit justifies the possible risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy using either an ARB or a calcium‑channel blocker, the Olmesartan+amlodipine fixed‑dose offers greater blood‑pressure reduction through two complementary pathways. It can replace the need for multiple separate pills, improving adherence, while maintaining a safety profile similar to the individual agents.

Store the tablets at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep them out of reach of children and do not use the product after the expiry date printed on the packaging.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events include angio‑edema, severe hypotension, hepatic dysfunction, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience swelling of the face or throat, marked dizziness, or any signs of an allergic reaction.

The combination should be avoided in patients with known hypersensitivity to olmesartan, amlodipine or any excipients, in those with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for individuals with significant renal dysfunction.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT